Patents by Inventor Lisa Dietz

Lisa Dietz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPECIFIC ANTIBODY DRUG CONJUGATES (ADCS) HAVING KSP INHIBITORS
    Publication number: 20190365916
    Abstract: Specific binder-drug conjugates (ADCs) of kinesin spindle protein inhibitors, effective metabolites of these ADCs, processes for preparing these ADCs, the use of these ADCs for the treatment and/or prevention of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases, are described.
    Type: Application
    Filed: December 18, 2017
    Publication date: December 5, 2019
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Sandra BERNDT, Lisa DIETZ, Stephan MÄRSCH, Stefanie HAMMER
  • PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS
    Publication number: 20190351066
    Abstract: The invention relates to novel prodrugs or conjugates of the general formula (Ia) in which La, n, R and D have the definitions given in the description and which have a structural motif reduced to an asparagine derivative as cleavage site for tumour-associated proteases such as legumain, in which cytotoxic drugs, for example kinesin spindle protein inhibitors, are released by legumain cleavage, and to the use of these prodrugs or conjugates for treatment and/or prevention of diseases, and to the use of these prodrugs or conjugates for production of medicaments for treatment and/or prevention of diseases, especially of hyperproliferative and/or angiogenic disorders, for example cancers. Reduction of the legumain-cleavable substrate peptide sequence to an asparagine derivative as structural motif, as a result of slowed legumain cleavage, achieves an increase in stability in the lysosomes of healthy organs while simultaneously maintaining the high anti-tumour effect.
    Type: Application
    Filed: December 18, 2017
    Publication date: November 21, 2019
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Leo MARX, Sarah Anna Liesa JOHANNES, Beatrix STELTE-LUDWIG, Lisa DIETZ, Hannah JOERISSEN, Christoph MAHLERT, Simone GREVEN, Anette SOMMER
  • ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS
    Publication number: 20190328897
    Abstract: The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.
    Type: Application
    Filed: December 14, 2017
    Publication date: October 31, 2019
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Beatrix STELTE-LUDWIG, Dennis KIRCHHOFF, Lisa DIETZ, Christoph MAHLERT, Simone GREVEN, Stephan MÄRSCH, Sandra BERNDT, Anette SOMMER, Stefanie HAMMER
  • Heteroaryl-substituted imidazo[1,2-A]pyridines and their use
    Patent number: 10292970
    Abstract: The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: May 21, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Volkhart Min-Jian Li
  • PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS
    Publication number: 20190077752
    Abstract: The invention relates to novel prodrugs or conjugates of the general formula (Ia) in which cytotoxic drugs, for example kinesin spindle protein inhibitors, are masked with legumain-cleavable groups and hence release the drug, and to the use of these prodrugs or conjugates for treatment and/or prevention of diseases, and to the use of these prodrugs or conjugates for production of medicaments for treatment and/or prevention of diseases, especially of hyperproliferative and/or angiogenic disorders, for example cancers.
    Type: Application
    Filed: March 21, 2017
    Publication date: March 14, 2019
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Leo MARX, Sarah Anna Liesa JOHANNES, Beatrix STELTE-LUDWIG, Lisa DIETZ, Carsten TERJUNG, Christoph MAHLERT, Simone GREVEN, Anette SOMMER, Sandra BERNDT
  • Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof
    Patent number: 10214526
    Abstract: The present application relates to novel substituted pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: February 26, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Min Jian Volkhart Li
  • Substituted pyrazolo[1,5-A]pyridines and their use
    Patent number: 10174021
    Abstract: The present application relates to novel substituted pyrazolo[1,5-a]pyridines of the formula (I-A) to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: January 8, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Volkhart Min-Jian Li
  • N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6- dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (SGC) for the treatment of cardiovascular diseases
    Patent number: 10150773
    Abstract: The present application relates to novel substituted imidazo[1,2-a]pyrazine carboxamides of general formula (I) to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: December 11, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandros Vakalopoulos, Damian Brockschnieder, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Lisa Dietz, Min Jian Volkhart Li
  • ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-TWEAKR-ANTIBODIES
    Publication number: 20180318438
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 20, 2016
    Publication date: November 8, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Beatrix STELTE-LUDWIG, Stephan MÄRSCH, Uwe GRITZAN, Christoph MAHLERT, Simone GREVEN, Anette SOMMER, Sandra BERNDT, Lisa DIETZ
  • Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof
    Publication number: 20180037580
    Abstract: The present application relates to novel substituted pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: February 2, 2016
    Publication date: February 8, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandros VAKALOPOULOS, Damian BROCKSCHNIEDER, Frank WUNDER, Johannes-Peter STASCH, Tobias MARQUARDT, Lisa DIETZ, Min Jian Volkhart LI
  • N-SUBSTITUTED 8-[(2,6-DIFLUOROBENZYL)OXY]-2,6-DIMETHYLIMIDAZO[1,2-A]PYRAZIN-3-CARBOXAMIDE DERIVATIVES AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE (SGC) FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
    Publication number: 20180022751
    Abstract: The present application relates to novel substituted imidazo[1,2-a]pyrazine carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: February 2, 2016
    Publication date: January 25, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandros VAKALOPOULOS, Damian BROCKSCHNIEDER, Frank WUNDER, Johannes-Peter STASCH, Tobias MARQUARDT, Lisa DIETZ, Min Jian Volkhart LI
  • SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINES AND IMIDAZO[1,2-A]PYRAZINES AND THEIR USE
    Publication number: 20170313700
    Abstract: The present application relates to novel substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: November 30, 2015
    Publication date: November 2, 2017
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros VAKALOPOULOS, Damian BROCKSCHNIEDER, Frank WUNDER, Johannes-Peter STASCH, Tobias MARQUARDT, Lisa DIETZ, Volkhart Min-Jian LI
  • HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE
    Publication number: 20170304278
    Abstract: The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: November 30, 2015
    Publication date: October 26, 2017
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros VAKALOPOULOS, Damian BROCKSCHNIEDER, Frank WUNDER, Johannes-Peter STASCH, Tobias MARQUARDT, Lisa DIETZ, Volkhart Min-Jian LI
  • Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use
    Patent number: 9771360
    Abstract: The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: September 26, 2017
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros Vakalopoulos, Philipp Buchgraber, Niels Lindner, Markus Follmann, Frank Wunder, Johannes-Peter Stasch, Tobias Marquardt, Gorden Redlich, Lisa Dietz, Volkhart Min-Jian Li
  • AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF
    Publication number: 20170240566
    Abstract: The present application relates to novel amino-substituted fused pyrimidines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: August 25, 2015
    Publication date: August 24, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandros VAKALOPOULOS, Gaelle VALOT, Markus FOLLMANN, Damian BROCKSCHNIEDER, Johannes-Peter STASCH, Tobias MARQUARDT, Adrian TERSTEEGEN, Frank WUNDER, Lisa DIETZ, Dieter LANG, Ursula KRENZ
  • SUBSTITUTED QUINOLINE-4-CARBOXAMIDES AND USE THEREOF
    Publication number: 20170233345
    Abstract: The present application relates to novel substituted quinoline-4-carboxamides and use thereof, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: August 11, 2015
    Publication date: August 17, 2017
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Alexandros VAKALOPOULOS, Gaelle VALOT, Niels LINDNER, Markus FOLLMANN, Johannes-Peter STASCH, Frank WUNDER, Tobias MARQUARDT, Lisa DIETZ, Volkhart Min-Jian LI
  • SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF
    Publication number: 20170233413
    Abstract: The present application relates to novel substituted fused pyrimidines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: August 25, 2015
    Publication date: August 17, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Walter HÜBSCH, Alexandros VAKALOPOULOS, Markus FOLLMANN, Gaelle VALOT, Johannes-Peter STASCH, Damian BROCKSCHNIEDER, Tobias MARQUARDT, Frank WUNDER, Adrian TERSTEEGEN, Lisa DIETZ, Dieter LANG, Niels LINDNER
  • CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE
    Publication number: 20170217954
    Abstract: The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: March 18, 2015
    Publication date: August 3, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandros VAKALOPOULOS, Philipp BUCHGRABER, Niels LINDNER, Markus FOLLMANN, Frank WUNDER, Johannes-Peter STASCH, Tobias MARQUARDT, Gorden REDLICH, Lisa DIETZ, Volkhart Min-Jian LI
  • 6-CHLORINE-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS
    Publication number: 20170101407
    Abstract: The present application relates to novel 6-chloro-substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: April 29, 2015
    Publication date: April 13, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandros VAKALOPOULOS, Markus FOLLMANN, Johannes-Peter STASCH, Frank WUNDER, Tobias MARQUARDT, Lisa DIETZ, Dieter LANG, Volkhart Min-Jian LI
  • SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE
    Publication number: 20170057954
    Abstract: The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: March 19, 2015
    Publication date: March 2, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Alexandros VAKALOPOULOS, Gaelle VALOT, Niels LINDNER, Markus FOLLMANN, Frank WUNDER, Johannes-Peter STASCH, Tobias MARQUARDT, Gorden REDLICH, Lisa DIETZ, Volkhart Min-Jian Ll